CHD1L Protein is overexpressed in human ovarian carcinomas and is a novel predictive biomarker for patients survival

Table 3 Clinical pathogical parameters and expression of CHD1L for prognosis of 102 patients with ovarian carcinoma by univariate survival analysis (log-rank test)

Variable	All cases	Mean survival (months)	Median survival (months)	P value
Age at surgery				0.75
≤ 51^a	54	74.4	NR^b
> 51	48	92.9	NR^b
Histological type
Serous	72	78.4	NR^b	0.55
Mucinous	11	62.7	45
Others^c	19	88.4	NR^b
Histologicalgrade (Silveberg)				0.00
G1	16	116.3	NR^b
G2	61	87.5	NR^b
G3	25	33.3	22
FIGO stage				0.00
I	19	57.2	NR^b
II	10	59.1	NR^b
III	58	34.1	NR^b
IV	15	21.6	NR^b
Operation				0.00
Satisfactory cytoreductive operation	35	92.3	NR^b
Stage operation	32	121.4	NR^b
Unsatisfactory cytoreductive operation	25	47.6	22
Chemical program				0.17
TP	17	62.0	NR^b
Cyclophosphamide + Adriamycin + Carbo	41	83.5	66
Others	44	63.6	NR^b
Residual tumor				0.00
None	32	121.2	NR^b
<=2cm	35	92.3	NR^b
>2cm	35	46.5	22
CHD1L protein expression				0.03
Negative	50	97.4	NR^b
Positive	52	66.7	37

ISSN: 1471-2407